Status | Study |
Active, not recruiting |
Study Name: Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis Condition: Desmoid Tumors Aggressive Fibromatosis Date: 2013-10-31 Interventions: Drug: PF-03084014 Treatment with the selective small-molecule >=-secretase inhibitor PF- 3084014 caus |
Recruiting |
Study Name: Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors Condition: The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an Adjuvant Ther Date: 2013-06-26 Interventions: Drug: 5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug. |
Recruiting |
Study Name: PAZOPANIB Efficacy and Tolerance in Desmoids Tumors Condition: Progressive Desmoids Tumors Date: 2012-11-06 Interventions: Drug: PAZOPANIB treatment |
Completed |
Study Name: A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome Condition: Gardner Syndrome Colorectal Carcinoma Date: 2011-01-25 |
Recruiting |
Study Name: Endoxifen in Adults With Hormone Receptor Positive Solid Tumors Condition: Hormone Receptor-Positive Breast Gynecologic Date: 2011-01-07 Interventions: Drug: Z-Endoxifen Genetic polymorphisms in CYP2D6 and concomitant medications alter tamoxifen metabolism |
Recruiting |
Study Name: A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis Condition: Desmoid Tumor Date: 2010-12-06 Interventions: Drug: Sirolimus Loading do |
Completed |
Study Name: Study to Evaluate Imatinib in Desmoid Tumors Condition: Aggressive Fibromatosis Desmoid Tumor Date: 2010-06-02 Interventions: Drug: Imatinib 800 mg Other Name: Glivec |
Withdrawn |
Study Name: Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors Condition: Desmoid Tumors Fibromatosis Date: 2009-09-15 Interventions: Drug: Hydroxyurea Patients will take oral hydroxyurea with a starting dose of 20 mg/kg daily. Patients w |
Active, not recruiting |
Study Name: Imatinib in Patients With Desmoid Tumor and Chondrosarcoma Condition: Advanced Desmoid Tumor Advanced Chondrosarcoma Date: 2009-06-25 Interventions: Drug: Imatinib Mesylate 800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months |
Recruiting |
Study Name: Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma Condition: Adult Rhabdomyosarcoma Childhood Desmoplastic Small Round Cell Tumor Date: 2009-06-11 Interventions: Other: biologic sample preservation procedure |